Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Tax Provisions (2018 - 2024)

Historic Tax Provisions for BioNexus Gene Lab (BGLC) over the last 7 years, with Q4 2024 value amounting to -$80701.0.

  • BioNexus Gene Lab's Tax Provisions rose 1760.5% to -$80701.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$80701.0, marking a year-over-year decrease of 3257.27%. This contributed to the annual value of -$3494.0 for FY2024, which is 8376.85% up from last year.
  • BioNexus Gene Lab's Tax Provisions amounted to -$80701.0 in Q4 2024, which was up 1760.5% from $1555.0 recorded in Q3 2024.
  • In the past 5 years, BioNexus Gene Lab's Tax Provisions ranged from a high of $171488.0 in Q4 2020 and a low of -$474732.0 during Q4 2021
  • Over the past 5 years, BioNexus Gene Lab's median Tax Provisions value was $860.0 (recorded in 2020), while the average stood at -$12442.4.
  • Examining YoY changes over the last 5 years, BioNexus Gene Lab's Tax Provisions showed a top increase of 2213408.62% in 2021 and a maximum decrease of 37683.1% in 2021.
  • BioNexus Gene Lab's Tax Provisions (Quarter) stood at $171488.0 in 2020, then crashed by 376.83% to -$474732.0 in 2021, then skyrocketed by 84.18% to -$75102.0 in 2022, then crashed by 30.41% to -$97944.0 in 2023, then increased by 17.6% to -$80701.0 in 2024.
  • Its last three reported values are -$80701.0 in Q4 2024, $1555.0 for Q3 2024, and $55584.0 during Q2 2024.